Compare Amgen, Inc. (AMGN) vs Sprott Uranium Miners ETF (URNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Sprott Uranium Miners ETF — how do they compare? Amgen, Inc. trades at $356.92 (market cap $196.12B), while Sprott Uranium Miners ETF trades at $50.68. The key difference: Amgen, Inc. pays a 2.77% dividend while Sprott Uranium Miners ETF pays none, and Amgen, Inc. is trading nearer its 52-week high, Sprott Uranium Miners ETF nearer its low. Which is the better fit depends on your goals.
| AMGN | URNM | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $388.16 | $83.99 |
52-Week Low | $271.18 | $44.14 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
URNM trades at $53.29, up 2.07% today, but faces bearish technical signals with 15 sell indicators versus 4 buy signals. The uranium miner ETF benefits from AI-driven power demand, with Seeking Alpha highlighting a 'nuclear renaissance' thesis (June 12, 2026), though concentration in miners like Cameco poses risks. Financial ratios are unavailable, limiting fundamental clarity.
Outlook hinges on uranium supply-demand dynamics and AI energy needs, but technical weakness and mixed sentiment suggest cautious entry. Risks include miner concentration and spot price volatility, while institutional interest in nuclear energy offers long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Sprott Uranium Miners ETF
URNM is a pure-play ETF that invests in the global uranium industry. It provides exposure to companies involved in the mining, exploration, and production of uranium, as well as physical uranium holdings, with top assets like Cameco, Uranium Energy Corp, and the Sprott Physical Uranium Trust.
Read more on URNM →
